Mumbai, Sept. 28 -- Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.

Published by HT Digital Content Services with permission from Capital Market....